Literature DB >> 19802583

Dengue vaccine candidates in development.

Anna P Durbin1, Stephen S Whitehead.   

Abstract

Each of the DENV serotypes can cause the full spectrum of dengue illness. Epidemiological studies have implicated preexisting heterotypic DENV antibody as a risk factor for more severe disease upon secondary DENV infection. For these reasons, a successful DENV vaccine must protect against all four DENV serotypes. Live attenuated DENV vaccine candidates are the furthest along in development and clinical evaluation. Two live attenuated tetravalent vaccine candidates are in Phase 2 clinical trials in DENV endemic regions. Numerous other vaccine candidates including inactivated whole virus, recombinant subunit protein, DNA and virus-vectored vaccines are also under development. Those DENV vaccine candidates that have been evaluated in preclinical animal models or in clinical trials will be discussed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19802583     DOI： 10.1007/978-3-642-02215-9_10

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


  44 in total

1.  A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis.

Authors:  Dixon Grant; Grace K Tan; Min Qing; Jowin K W Ng; Andy Yip; Gang Zou; Xuping Xie; Zhiming Yuan; Mark J Schreiber; Wouter Schul; Pei-Yong Shi; Sylvie Alonso
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  In Memoriam: Robert M. Chanock, MD, 1924–2010.

Authors:  Albert Z Kapikian; David M Morens; Anthony S Fauci
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.

Authors:  Anke Harenberg; Sarah Begue; Audrey Mamessier; Sophie Gimenez-Fourage; Ching Ching Seah; Ai Wei Liang; Jun Li Ng; Xue Yun Toh; Sophia Archuleta; Annelies Wilder-Smith; Lynette P Shek; Anh Wartel-Tram; Alain Bouckenooghe; Jean Lang; Denis Crevat; Catherine Caillet; Bruno Guy
Journal:  Hum Vaccin Immunother       Date:  2013-07-09       Impact factor: 3.452

4.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 5.  Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis.

Authors:  Benjamin M Althouse; Anna P Durbin; Kathryn A Hanley; Scott B Halstead; Scott C Weaver; Derek A T Cummings
Journal:  Virology       Date:  2014-02-14       Impact factor: 3.616

Review 6.  Zika Virus: Immunity and Vaccine Development.

Authors:  Theodore C Pierson; Barney S Graham
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582

Review 7.  Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus.

Authors:  Kathryn A Hanley; Thomas P Monath; Scott C Weaver; Shannan L Rossi; Rebecca L Richman; Nikos Vasilakis
Journal:  Infect Genet Evol       Date:  2013-03-20       Impact factor: 3.342

8.  "Manifesto" for advancing the control and elimination of neglected tropical diseases.

Authors:  Peter J Hotez; Bernard Pecoul
Journal:  PLoS Negl Trop Dis       Date:  2010-05-25

9.  Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.

Authors:  Joshua M Costin; Elena Zaitseva; Kristen M Kahle; Cindo O Nicholson; Dawne K Rowe; Amanda S Graham; Lindsey E Bazzone; Greg Hogancamp; Marielys Figueroa Sierra; Rachel H Fong; Sung-Tae Yang; Li Lin; James E Robinson; Benjamin J Doranz; Leonid V Chernomordik; Scott F Michael; John S Schieffelin; Sharon Isern
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  Reduced risk of disease during postsecondary dengue virus infections.

Authors:  Sandra Olkowski; Brett M Forshey; Amy C Morrison; Claudio Rocha; Stalin Vilcarromero; Eric S Halsey; Tadeusz J Kochel; Thomas W Scott; Steven T Stoddard
Journal:  J Infect Dis       Date:  2013-06-17       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.